Localization of streptolydigin resistant mutation in E. coli chromosome and effect of streptolydigin on T2 phage development in stl-r and stl-s strains of E. coli

Sokolova, E. V.; Ovadis, Marianna; Gorlenko, Zh. M.; Khesin, R. B.

doi:10.1016/0006-291x(70)90164-6

Cited by 22 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sokolova et al [78] explored the impact of rifampin and streptolydigin on phage T2 infection (MOI << 1) of both antibiotic-susceptible and -resistant E. coli. Absent either drug, burst size was on the order of 200 in the doubly susceptible bacterium (rifampin and streptolydigin) but only 100 in the doubly resistant bacterium, suggesting existence of costs in phage infection activity associated with host antibiotic resistance.…”

Section: Sokolova Et Al 1970 Escherichia Coli Rifampin and Streptmentioning

confidence: 99%

Phage-Antibiotic Combination Treatments: Antagonistic Impacts of Antibiotics on the Pharmacodynamics of Phage Therapy?

Abedon

2019

Antibiotics

104

View full text Add to dashboard Cite

Bacteria can evolve resistance to antibiotics. Even without changing genetically, bacteria also can display tolerance to antibiotic treatments. Many antibiotics are also broadly acting, as can result in excessive modifications of body microbiomes. Particularly for antibiotics of last resort or in treating extremely ill patients, antibiotics furthermore can display excessive toxicities. Antibiotics nevertheless remain the standard of care for bacterial infections, and rightly so given their long track records of both antibacterial efficacy and infrequency of severe side effects. Antibiotics do not successfully cure all treated bacterial infections, however, thereby providing a utility to alternative antibacterial approaches. One such approach is the use of bacteriophages, the viruses of bacteria. This nearly 100-year-old bactericidal, anti-infection technology can be effective against antibiotic-resistant or -tolerant bacteria, including bacterial biofilms and persister cells. Ideally phages could be used in combination with standard antibiotics while retaining their anti-bacterial pharmacodynamic activity, this despite antibiotics interfering with aspects of bacterial metabolism that are also required for full phage infection activity. Here I examine the literature of pre-clinical phage-antibiotic combination treatments, with emphasis on antibiotic-susceptible bacterial targets. I review evidence of antibiotic interference with phage infection activity along with its converse: phage antibacterial functioning despite antibiotic presence.

show abstract

Section: Sokolova Et Al 1970 Escherichia Coli Rifampin and Streptmentioning

confidence: 99%

Phage-Antibiotic Combination Treatments: Antagonistic Impacts of Antibiotics on the Pharmacodynamics of Phage Therapy?

Abedon

2019

Antibiotics

104

View full text Add to dashboard Cite

show abstract

“…All the rifampicin-resistant mutants that have been mapped in E. coli ei ther by conjugation (78)(79)(80)(82)(83)(84)(85)(86)(87) or by transduction (48,49,101), are located near the arg H locus. Temperature-sensitive mutants have.…”

Section: Mutation To Rifampicin Resistancementioning

confidence: 99%

Rifamycins: A General View

Riva¹,

Silvestri²

1972

Annu. Rev. Microbiol.

127

View full text Add to dashboard Cite

“…Rather high concentrations of streptolydigin are needed to obtain inhibition. Resistance to this substance is due either to changes in cell permeability or to a modified RNA polymerase (136,153). In contrast to rifamycin, however, complete resistance to streptolydigin has not been observed.…”

Section: Compounds Related To Thementioning

confidence: 99%